Q3 2025 IRIDEX Corp Earnings Call Transcript
Key Points
- IRIDEX Corp (IRIX) achieved a fourth consecutive quarter of year-over-year revenue growth, with an 8% increase in the third quarter.
- The company reduced operating expenses by 12% in the third quarter, contributing to improved financial performance.
- IRIDEX Corp (IRIX) is on track to achieve positive cash flows in the fourth quarter and positive adjusted EBITDA for the full year 2025.
- The Cyclo G6 glaucoma product group saw a 13% year-over-year revenue growth, driven by increased sales of probes and systems.
- The company is implementing cost-saving measures, such as relocating certain functions outside of California, expected to generate significant savings starting in 2026.
- Gross margin decreased by 520 basis points due to a $0.8 million charge related to inventory write-downs.
- The company faced operational challenges in Asia, including the ongoing tariff dispute with China and currency-driven competitive pressures in Japan.
- Retina product revenue growth was partially offset by a decrease in surgical retina probe sales.
- The transition to third-party contract manufacturers resulted in excess and obsolete inventory, impacting financial results.
- Cash and cash equivalents decreased by $1.2 million from the second quarter to the third quarter of 2025.
Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the third quarter 2025 IRIDEX earnings conference call.
I would now like to turn the conference over to Trip Taylor, Investor Relations. You may begin.
Thank you, and thank you all for participating in today's call. Joining me from the company are Patrick Mercer, IRIDEX's Chief Executive Officer; and Romeo Dizon, the company's Chief Financial Officer. Earlier today, IRIDEX released financial results for the quarter ended September 27, 2025. A copy of the press release is available on the company's website.
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts including, but not limited to,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
